Glasdegib (original) (raw)
Le glasdegib est un médicament indiqué dans le traitement de la leucémie aigüe myéloïde. C'est une thérapie ciblée, inhibant la voie Hedgehog. Son utilisation a été approuvée aux États-Unis en 2018 et Europe en 2020.
| Property | Value |
|---|---|
| dbo:abstract | Glasdegib, sold under the brand name Daurismo, is a medication for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults older than 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy. It is taken by mouth and is used in combination with low-dose cytarabine. The recommended dose of glasdegib is 100 mg orally once daily on days 1 to 28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control. The most common adverse reactions are anemia, fatigue, hemorrhage, febrile neutropenia, musculoskeletal pain, nausea, edema, thrombocytopenia, dyspnea, decreased appetite, dysgeusia, mucositis, constipation, and rash. It is a small molecule inhibitor of sonic hedgehog, which is a protein overexpressed in many types of cancer. It inhibits the sonic hedgehog receptor smoothened (SMO), as do most drugs in its class. (en) Le glasdegib est un médicament indiqué dans le traitement de la leucémie aigüe myéloïde. C'est une thérapie ciblée, inhibant la voie Hedgehog. Son utilisation a été approuvée aux États-Unis en 2018 et Europe en 2020. (fr) |
| dbo:alternativeName | Daurismo (en) |
| dbo:casNumber | 1095173-27-5 |
| dbo:chEBI | 145428 |
| dbo:chEMBL | 2043437 |
| dbo:drugbank | DB11978 |
| dbo:fdaUniiCode | K673DMO5H9 |
| dbo:kegg | D10636 D11107 |
| dbo:medlinePlus | a619004 |
| dbo:pubchem | 25166913 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Glasdegib.svg?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/glasdegib |
| dbo:wikiPageID | 52923863 (xsd:integer) |
| dbo:wikiPageLength | 8693 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1090921428 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Priority_review dbc:Pfizer_brands dbc:Piperidines dbc:Ureas dbr:Orphan_drug dbc:Benzimidazoles dbc:Orphan_drugs dbr:Cytarabine dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbc:Antineoplastic_drugs dbc:Nitriles dbc:Teratogens dbr:Sonic_hedgehog dbr:Smoothened |
| dbp:atcPrefix | L01 (en) |
| dbp:atcSuffix | XJ03 (en) |
| dbp:c | 21 (xsd:integer) |
| dbp:casNumber | 1095173 (xsd:integer) |
| dbp:chebi | 145428 (xsd:integer) |
| dbp:chembl | 2043437 (xsd:integer) |
| dbp:chemspiderid | 28518072 (xsd:integer) |
| dbp:drugbank | DB11978 (en) |
| dbp:h | 22 (xsd:integer) |
| dbp:index2Label | as salt (en) |
| dbp:iupacName | 1 (xsd:integer) |
| dbp:kegg | D10636 (en) D11107 (en) |
| dbp:legalCa | Rx-only (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:medlineplus | a619004 (en) |
| dbp:n | 6 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pubchem | 25166913 (xsd:integer) |
| dbp:smiles | CN1CCCNCNC4=CC=CC#N (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | SFNSLLSYNZWZQG-VQIMIIECSA-N (en) |
| dbp:synonyms | PF-04449913 (en) |
| dbp:tradename | Daurismo (en) |
| dbp:unii | K673DMO5H9 (en) |
| dbp:wikiPageUsesTemplate | dbt:Chemotherapeutic_agents dbt:Antineoplastic-drug-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Fdacite dbt:Keggcite dbt:Drugs.com dbt:ClinicalTrialsGov |
| dct:subject | dbc:Pfizer_brands dbc:Piperidines dbc:Ureas dbc:Benzimidazoles dbc:Orphan_drugs dbc:Antineoplastic_drugs dbc:Nitriles dbc:Teratogens |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Le glasdegib est un médicament indiqué dans le traitement de la leucémie aigüe myéloïde. C'est une thérapie ciblée, inhibant la voie Hedgehog. Son utilisation a été approuvée aux États-Unis en 2018 et Europe en 2020. (fr) Glasdegib, sold under the brand name Daurismo, is a medication for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults older than 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy. It is taken by mouth and is used in combination with low-dose cytarabine. The recommended dose of glasdegib is 100 mg orally once daily on days 1 to 28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control. (en) |
| rdfs:label | Glasdegib (fr) Glasdegib (en) |
| owl:sameAs | yago-res:Glasdegib wikidata:Glasdegib dbpedia-fr:Glasdegib https://global.dbpedia.org/id/2XuvX |
| prov:wasDerivedFrom | wikipedia-en:Glasdegib?oldid=1090921428&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Glasdegib.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Glasdegib |
| is dbo:wikiPageRedirects of | dbr:Daurismo dbr:Glasdegib_maleate dbr:C21H22N6O dbr:PF-04449913 |
| is dbo:wikiPageWikiLink of | dbr:Daurismo dbr:Glasdegib_maleate dbr:C21H22N6O dbr:Hedgehog_pathway_inhibitor dbr:ATC_code_L01 dbr:Smoothened dbr:PF-04449913 |
| is foaf:primaryTopic of | wikipedia-en:Glasdegib |
